(PATH)and is notcovered here47.
published by the Program for Appropriate Technology in Healt
manufacturing has been discussed exhaustively in a repor
especially in a pandemic situation. This aspect of the vaccin
to ensure adequate supply of vaccine at an affordable cost
manufacturing processes and technologies are critical element
vaccines to the market. The yield and the cost of variou
annually.Italso raises thecostand thetime ittakestobringth
a constraint for the commercial scale manufacturing of vaccine
disassemblyandreassemblyprocessingofpurifiedVLPs,whichi
these unwanted proteins from the vaccine required extensiv
integrated both baculovirus and Sf9 cell proteins. Elimination o
purity of the vaccines considerably, as VLP structures als
structures enhanced their immunogenicity, it compromised th
expressedininsectcells44â€“46.AlthoughpresentingproteinsinVL
by integrating HA, capsid protein (M1) and neuraminidase (NA